Mansfield, Aaron S. http://orcid.org/0000-0002-9483-6903
Hong, David S.
Hann, Christine L.
Farago, Anna F.
Beltran, Himisha http://orcid.org/0000-0003-3259-2226
Waqar, Saiama N.
Hendifar, Andrew E.
Anthony, Lowell B.
Taylor, Matthew H.
Bryce, Alan H. http://orcid.org/0000-0002-0206-3895
Tagawa, Scott T. http://orcid.org/0000-0003-2777-8587
Lewis, Karl
Niu, Jiaxin
Chung, Christine H.
Cleary, James M.
Rossi, Michael
Ludwig, Carrianne
Valenzuela, Ricardo
Luo, Yan
Aggarwal, Rahul http://orcid.org/0000-0001-7003-7982
Funding for this research was provided by:
AbbVie
Article History
Received: 15 October 2020
Accepted: 14 July 2021
First Online: 5 August 2021
Competing interests
: A.S.M. reports honoraria to institution from AbbVie, AstraZeneca, Bristol Myers Squibb, and Genentech; research funding from the National Institutes of Health, Novartis, and Verily; nonremunerated director of Mesothelioma Applied Research Foundation. D.S.H. reports a leadership role or other ownership with OncoResponse, Molecular Match, and Presagia Inc.; a consultancy/advisory role for Alpha Insights, Amgen, Axiom, Adaptimmune, Baxter, Bayer, eCancer, Genentech, GLG, Group H, Guidepoint, Infinity, Medscape, Numab, Oncology Education Project Association, Pfizer, Prime Oncology, Takeda, Trieza Therapeutics, and WebMD; travel support from Bayer, Loxo, miRNA, Genmab, AACR, ASCO, and SITC; research funding from AbbVie, Adaptimmune, Aldi-Norte, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Eisai, Fate Therapeutics, Genentech, Genmab, GlaxoSmithKline, Ignyta, Infinity, Kite, Kyowa, Eli Lilly, Loxo Oncology, Merck, MedImmune, Mirati Therapeutics, miRNA, Molecular Templates, MOLOGEN AG, NCI-CTEP, Novartis, Pfizer, Seattle Genetics, Takeda, and Turning Point Therapeutics. C.L.H. reports a consultancy/advisory role with AbbVie, Ascentage Pharma, Bristol Myers Squibb, and Genentech; research funding to institution from AbbVie, Amgen, AstraZeneca, and Bristol Myers Squibb. A.F.F. reports a consultancy/advisory role with Bayer, Loxo Oncology, Genentech, Roche, Bristol Myers Squibb, AstraZeneca, AbbVie, PharmaMar, Boehringer Ingelheim, Merck, H3 Biomedicine, and Pfizer; research funding from Bayer, Loxo Oncology, Genentech, Roche, Bristol Myers Squibb, AstraZeneca, AbbVie, PharmaMar, Merck, Ignyta, Amgen, and Novartis; honoraria from DAVA Oncology, Clinical Care Options, Medical Learning Institute, Medscape, PeerView, and Research to Practice. H.B. reports a consultancy/advisory role with Janssen, Sanofi Genzyme, Pfizer, Astellas, AstraZeneca, and Merck; research funding from AbbVie/Stemcentrx; research funding to institution from Janssen Oncology, Eli Lilly, and Millennium Pharmaceuticals. S.N.W. reports research funding to institution from Spectrum Pharmaceuticals, Eli Lilly, Pfizer, Roche/Genentech, Daiichi Sankyo, NewLink Genetics, EMD Serono, Puma Biotechnology, Novartis, Xcovery, Synermore Biologics, Celgene, Vertex, Bristol Myers Squibb, Stemcentrx, Hengrui Therapeutics, Checkpoint Therapeutics, Ignyta, AstraZeneca, ARIAD, Roche, and Merck. A.E.H. reports a consultancy/advisory role with Novartis, Ipsen, Perthera, Celgene, and AbbVie; research funding from AbbVie; travel accommodations from Halozyme. L.B.A. reports a consultancy/advisory role for Lexicon; research funding to institution from AbbVie, Oncotelic, and Entrinsic Health Solutions. M.H.T. reports a consultancy/advisory role with and honoraria from Bristol Myers Squibb, Eisai, Novartis, Bayer, Sanofi/Genzyme, Array Biopharma, Loxo Oncology, Blueprint Medicines, and Arqule; speakers’ bureau for and honoraria from Bristol Myers Squibb and Eisai. A.H.B. reports honoraria from Astellas Pharma and Bayer; travel support from Clovis Oncology. S.T.T. reports a consultancy/advisory role for Medivation, Astellas Pharma, Dendreon, Janssen, Bayer, Genentech, Endocyte, Immunomedics, Karyopharm Therapeutics, AbbVie, Tolmar, QED Therapeutics, Amgen, Sanofi, Pfizer, Clovis Oncology, Novartis, and Genomic Health, POINT Biopharma, Blue Earth Diagnostics, Aikido Pharma, Telix Pharma; travel support from Sanofi, Immunomedics, and Amgen; research funding to institution from Eli Lilly, Sanofi, Janssen, Astellas Pharma, Progenics, Millennium, Amgen, Bristol Myers Squibb, Dendreon, Rexahn Pharmaceuticals, Bayer, Genentech, NewLink Genetics, Inovio Pharmaceuticals, AstraZeneca, Immunomedics, Novartis, AVEO, Boehringer Ingelheim, Merck, Stemcentrx, Karyopharm Therapeutics, AbbVie, Medivation, Endocyte, Exelixis, Clovis Oncology, SeaGen, and Gilead. K.L. reports a consultancy/advisory role for Array BioPharma, Merck, Roche, and Regeneron; honoraria from Array BioPharma; travel support from Merck, Roche/Genentech, and Regeneron; research funding to the institution from Roche/Genentech, Merck, Array BioPharma, Incyte, Nektar, Iovance Biotherapeutics, Bristol Myers Squibb, Kartos Therapeutics, OncoSec, Regeneron, Alkermes, and Neon Therapeutics; uncompensated relationship with Roche/Genentech and Regeneron. J.N. reports a consultancy/advisory role for Roche and Boehringer Ingelheim; honoraria from Onclive. C.H.C. reports a consultancy/advisory role for Bristol Myers Squibb, Mirati, CUE Biopharma, Sanofi, and Ignyta; travel support from Bristol Myers Squibb; research funding from AstraZeneca, Bristol Myers Squibb, Eli Lilly, Merck, Regeneron, Ignyta, Brooklyn Therapeutics, Pfizer, and lovance. J.M.C. reports research funding from Merck, AstraZeneca, Esperas Pharma, and Tesaro; a consultancy/advisory role with Bristol Myers Squibb; travel funding from Bristol Myers Squibb. M.R. reports former employment by AbbVie, current employment with Calithera Biosciences, and may hold AbbVie stock. C.L., R.V., and Y.L. report employment by AbbVie and may own stock or other options. R.A. reports a consultancy/advisory role for AstraZeneca and Janssen; honoraria from Clovis Oncology; travel support from Xynomic Pharmaceuticals; institution received research funding from Zenith Epigenetics, Novartis, Xynomic Pharmaceuticals, Cancer Targeted Technology, Janssen, Merck, and AbbVie.